NCT07723963
A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Site details revised at 1 of 23 sites
- Minor Trial sites expanded: 19 → 23 locations
- Notable Recruitment opened
- Eligibility criteria expanded, about 12 words
- Study sites: 19 to 20
- Secondary endpoints: details revised at 1 of 9 entries
- Minor Trial sites expanded: 10 → 19 locations
- Start date: Sep 1, 2026 to Sep 18, 2026
- Minor Study title shortened, about 6 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change from baseline in myoclonic seizure days per 28 days (Part A and Part B)
Timeframe: Baseline up to end of 16 weeks treatment period
Secondary (9)
Patient and Caregiver Global Impression of Change in Usual Daily Activities (P/CaGI-C UDA) (Part A and Part B)
Proportion of participants who achieve ≥ 50% and ≥ 75% reduction from baseline in myoclonic seizure days (Part A and Part B)
Change from baseline in days with any seizure type per 28 days (Part A and Part B)
Number of days with fewer myoclonic seizures than participant average prior to entering the study per 28 days (Part A and Part B)
Percent change from baseline (historical + prospective) in generalized tonic-clonic (GTC) seizure frequency (Part A and Part B)
Show 4 moreShow less
Number of participants reporting treatment-emergent adverse events (Part A and Part B)
Mean plasma concentration for CBD
Mean plasma concentration of metabolite 7-OH-CBD
Mean plasma concentration of metabolite 7-COOH-CBD
Arms and interventions
JZP926 CapsuleExperimental
Participants with JME will be randomized to JZP926 capsule based on weight-tiered dosing for a 16-week treatment period.
PlaceboPlacebo comparator
Participants with JME will be randomized to matching placebo based on weight-tiered dosing for a 16-week treatment period.
Open-Label Extension: JZP926 CapsuleExperimental
Participants completing Part A or Part B will have the option to continue into an open-label extension for up to 52 weeks, inclusive of a 4 week blinded transition.
Drugs: JZP926 capsule, Placebo
Sites
23 sites in 1 country